Zevra Therapeutics, Inc. (ZVRA)

US — Healthcare Sector
Peers:   RNAZ  FBIO  AKBA  TRVN  RVPH  GLUE  PMVP  PHVS  TYRA  MOLN  STOK  ANTX  PASG  FDMT  CCCC  FHTX  STTK 

Automate Your Wheel Strategy on ZVRA

With Tiblio's Option Bot, you can configure your own wheel strategy including ZVRA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ZVRA
  • Rev/Share 0.7503
  • Book/Share 0.7583
  • PB 12.2372
  • Debt/Equity 1.5074
  • CurrentRatio 3.0239
  • ROIC -0.5842

 

  • MktCap 507426688.0
  • FreeCF/Share -1.1428
  • PFCF -8.208
  • PE -5.4573
  • Debt/Assets 0.358
  • DivYield 0
  • ROE -2.0114

 

  • Rating
  • Score
  • Recommendation
  • P/E Score
  • DCF Score
  • P/B Score
  • D/E Score

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Resumed ZVRA Cantor Fitzgerald -- Overweight -- $25 Jan. 8, 2025
Initiation ZVRA Guggenheim -- Buy -- $20 Oct. 7, 2024
Initiation ZVRA JMP Securities -- Mkt Outperform -- $17 Sept. 24, 2024
Reiterated ZVRA Maxim Group -- Buy $18 $25 Sept. 24, 2024

News

All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director Nominees
ZVRA
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral

ISS, Glass Lewis, and Egan-Jones Unanimously Conclude Mangless Has Not Made a Compelling Case for Change Board and Management Urge Stockholders to Follow Proxy Advisors' Recommendation and Vote “FOR” Wendy L. Dixon, Ph.D.

Read More
image for news All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director Nominees
Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call
ZVRA
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral

Company will host conference call at 4:30 p.m. ET on Tuesday, May 13, 2025 Company will host conference call at 4:30 p.m. ET on Tuesday, May 13, 2025

Read More
image for news Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call
Zevra to Participate at Upcoming Investor Conferences
ZVRA
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral

CELEBRATION, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra's executive leadership team will participate at the following March events:

Read More
image for news Zevra to Participate at Upcoming Investor Conferences

About Zevra Therapeutics, Inc. (ZVRA)

  • IPO Date 2015-04-16
  • Website https://zevra.com
  • Industry Biotechnology
  • CEO Neil F. McFarlane
  • Employees 59
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase II clinical trial. In addition, the company has received FDA approval for AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. The company's product pipeline include, arimoclomol It has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.